Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: Results in 78 patients of the AutoImmune and Rituximab registry

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 1026-1031

  Gottenberg, Jacques Eric ^a   Cinquetti, Gael ^b   Larroche, Claire ^c   Combe, Bernard ^d   Hachulla, Eric ^e   Meyer, Olivier ^f   Pertuiset, Edouard ^g   Kaplanski, Guy ^h   Chiche, Laurent ^h   Berthelot, Jean Marie ⁱ   Gombert, Bruno ^j   Goupille, Philippe ^k   Marcelli, Christian ^l   Feuillet, Séevrine ^m   Leone, Jean ⁿ   Sibilia, Jean ^a   Zarnitsky, Charles ^o   Carli, Philippe ^p   Rist, Stephanie ^q   Gaudin, Philippe ^r   Salliot, Carine ^q   Piperno, Muriel ^s   Deplas, Adeline ^t   Breban, Maxime ^u   Lequerre, Thierry ^v   Richette, Pascal ^w   Ghiringhelli, Charles ^x   Hamidou, Mohamed ⁱ   Ravaud, Philippe ^y   Mariette, Xavier ^z   more..

^a UNIVERSITÉ DE STRASBOURG   (France)

^b HIA Legouest   (France)

^c AVICENNE HOSPITAL   (France)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f BICHAT HOSPITAL   (France)

^g Service de Rhumatologie   (France)

^h HÔPITAL DE LA CONCEPTION   (France)

ⁱ NANTES UNIVERSITY HOSPITAL   (France)

^j CH de La Rochelle   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

^l CAEN UNIVERSITY HOSPITAL   (France)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ SERVICE DE DERMATOLOGIE   (France)

^o LE HAVRE HOSPITAL   (France)

^p Military Teaching Hospital Sainte Anne   (France)

^q CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

^r Grenoble Teaching Hospital CHU Hôpital Sud   (France)

^s HOSPICES CIVILS DE LYON   (France)

^t CH Niort   (France)

^u HÔPITAL AMBROISE PARÉ   (France)

^v ROUEN UNIVERSITY HOSPITAL   (France)

^w HÔPITAL LARIBOISIÈRE   (France)

^x HÔPITAL SAINT ANDRÉ   (France)

^y INSERM   (France)

^z UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

ADULT; AGED; ALLERGIC URTICARIA; ANGIONEUROTIC EDEMA; ARTHROPATHY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE PANCREATITIS; AUTOIMMUNE THROMBOCYTOPENIA; CANCER MORTALITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EVALUATION; CYTOMEGALOVIRUS INFECTION; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFUSION RELATED REACTION; KIDNEY DISEASE; LACRIMAL GLAND DISEASE; LACRIMAL GLAND HYPERTROPHY; LIVER METASTASIS; LUNG DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYOSITIS; PAGET NIPPLE DISEASE; PAROTID GLAND DISEASE; PAROTID SWELLING; PERIPHERAL NEUROPATHY; PRIMARY SJOEGREN SYNDROME; PRIORITY JOURNAL; SERUM SICKNESS; SHOCK; SPINE METASTASIS; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCAL PNEUMONIA; SYNOVITIS; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VASCULITIS; VULVA CANCER;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; SJØGREN'S SYNDROME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGISTRIES; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84877611272     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202293     Document Type: Article

References (24)

1. Tzioufas AG, Vlachoyiannopoulos PG. Sjogren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects. J Autoimmun 2012;39:1-3.
2. Garcia-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 2002;81:270.
3. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;304:452-60.
4. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
5. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
6. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4.
7. Mariette X, Gottenberg J-E, Ravaud P, et al. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology 2010;50:222-9.
8. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20. (Pubitemid 40733918)
9. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 2007;66:351-7. (Pubitemid 46579637)
10. Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005;64:958-60. (Pubitemid 40733928)
11. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007;57:310-17. (Pubitemid 47164095)
12. Ramos-Casals M, Garcia-Hernandez F, De Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2010;28:468-76.
13. Tony H-P, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 2011;13:R75.
14. Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2011;71:84-7.
15. Mekinian A, Ravaud P, Larroche C, et al. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry. Clin Exp Rheumatol 2012;30:208-12.
16. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 2010;62:1787-95.
17. Voulgarelis M, Giannouli S, Anagnostou D, et al. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. Rheumatology 2004;43:1050-3. (Pubitemid 39144455)
18. Voulgarelis M, Giannouli S, Tzioufas AG, et al. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis 2006;65:1033-7. (Pubitemid 44133265)
19. Voulgarelis M, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome. Isr Med Assoc J 2001;3:761-6. (Pubitemid 34082747)
20. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoImmunity and rituximab registry. Arthritis Rheum 2010;62:2458-66.
21. Couderc M, Gottenberg J-E, Mariette X, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 2011;50:2283-9.
22. Pham T, Fautrel B, Gottenberg JE, et al. Rheumatic Diseases & Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR). Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008;75(Suppl. 1):S1-99.
23. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20.
24. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.